Clinical Study Evaluating Beta Blockers Use and Fracture Risk in Patients With Primary Osteoporosis

Beta Blocker Toxicity Clinical Trial

Official title:

Clinical Study Evaluating Selective or Nonselective Beta Blockers Use and Fracture Risk in Patients With Primary Osteoporosis

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT04704947
• Other study ID #: osteoprosis
• Status: Recruiting
• Phase: Phase 3
• Start date: October 1, 2017
• Est. completion date: October 1, 2030

Study information

• Verified date: January 2021
• Source: Tanta University
• Contact: Sherief Abd-Elsalam, ass. prof.
• Phone: 00201147773440
• Email: sheriefabdelsalam[@]yahoo.com
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

Clinical study evaluating selective or nonselective beta blockers use and fracture risk in patients with primary osteoporosis

Description:

Clinical study evaluating selective or nonselective beta blockers use and if there is fracture risk in patients with primary osteoporosis

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 50
• Est. completion date: October 1, 2030
• Est. primary completion date: October 1, 2030
• Accepts healthy volunteers: No
• Gender: All
• Age group: 50 Years and older

Eligibility

Inclusion Criteria:

• • Male & female osteoporotic patient aged = 50 years

• Hypertensive & normotensive patients

• BMD T-score = 2.5 or more SD below peak bone mass

Exclusion Criteria:

• Patients on drugs that may improve osteoporosis disease state such as:

• Angiotensin converting enzyme inhibitor (ACEI) or Angiotensin receptor blockers (ARBs), Thiazide diuretic, Nitrates, Spironolactone, Statins.

Patients on drugs that may worsen osteoporosis disease state such as:

• Corticosteroids, Loop diuretics, Anticonvulsants, Antidepressants, Aromatase inhibitors, Thyroid replacement therapy and Proton pump inhibitors.

Related Conditions & MeSH terms

• Beta Blocker Toxicity
• Osteoporosis

Intervention

Drug:
• nonselective beta blocker
nonselective beta blocker
• cardio-selective beta blocker group
cardio-selective beta blocker group
• alendronate sodium
alendronate sodium

Locations

Country	Name	City	State
Egypt	Sherief Abd-Elsalam	Tanta

Sponsors (1)

Lead Sponsor	Collaborator
Sherief Abd-Elsalam

Country where clinical trial is conducted

Egypt, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Number of patients with fracture in each group	the exact number of patients with fracture in each group	1 year